Fexofenadine
- Generic Name
- Fexofenadine
- Brand Names
- Allegra, Allegra-D, Mucinex Non-drowsy Allergy, Wal-fex, Telfast
- Drug Type
- Small Molecule
- Chemical Formula
- C32H39NO4
- CAS Number
- 83799-24-0
- Unique Ingredient Identifier
- E6582LOH6V
- Background
Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of terfenadine and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.
- Indication
In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Seasonal Allergic Rhinitis
- Associated Therapies
- Antihistamine
Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT00637455
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT00638118
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms
- Conditions
- Cat Induced Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT00637884
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT00637585
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1010
- Registration Number
- NCT00637611
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 220
- Registration Number
- NCT00636870
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00562120
- Locations
- 🇺🇸
Pfizer Investigational Site, Omaha, Nebraska, United States
Comparative Study Evaluating the Effects of Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice in a Skin Wheal and Flare Challenge Model.
- Conditions
- Allergy
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 36
- Registration Number
- NCT00547768
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 75
- Registration Number
- NCT00420082
- Locations
- 🇦🇹
Allergy Center Vienna West, Vienna, Austria
Fexofenadine in Pruritic Skin Disease
- Conditions
- Pruritus
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2007-11-07
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 435
- Registration Number
- NCT00261079
- Locations
- 🇰🇷
Handok, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.